 |
|
|
|
|
Massachusetts Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing MassachusettsLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Syros Pharmaceuticals
| | | | | Phone: | (617) 744-1340 | | Year Established: | 2011 | | Ticker: | SYRS | | Exchange: | NASDAQ | | Main Contact: | Nancy Simonian, M.D., CEO | | | | Other Contacts: | Kyle Kuvalanka, COO
Jorge Conde, Chief Strategy Officer
Gerald E.Quirk, CLO
David A. Roth, M.D., CMO
Eric R. Olson, Ph.D., CSO
| | | | Company Description | | Syros Pharmaceuticals is pioneering the understanding of the non-coding region of the genome to advance a new wave of medicines that control expression of disease-driving genes. Syros has built a proprietary platform that is designed to systematically and efficiently analyze this unexploited region of DNA in human disease tissue to identify and drug novel targets linked to genomically defined patient populations. Because gene expression is fundamental to the function of all cells, Syros’ gene control platform has broad potential to create medicines that achieve profound and durable benefit across a range of diseases. Syros is currently focused on cancer and immune-mediated diseases and is advancing a growing pipeline of gene control medicines. Syros’ lead drug candidates are SY-1425, a selective RAR? agonist in a Phase 2 clinical trial for genomically defined subsets of patients with acute myeloid leukemia and myelodysplastic syndrome, and SY-1365, a selective CDK7 inhibitor with potential in a range of solid tumors and blood cancers. | |
|
|
|
|
|
|
|
